NASDAQ$DSGN
Design Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported fourth quarter and full year financial results, highlighting pipeline progress.
Design Therapeutics reported its Q4 and full year 2022 financial results, highlighting the progress of its GeneTAC™ small molecules pipeline. The company's lead candidate, DT-216, showed promising initial results in a Phase 1 clinical trial for Friedreich ataxia, and the company is advancing its programs in FECD and DM1 towards clinical development.
- Phase 1 multiple-ascending dose trial of DT-216 for Friedreich Ataxia is ongoing with data expected mid-year.
- Continued progress across pipeline of GeneTAC™ small molecules with three programs expected to be in clinical development in the next two years.
- DT-168 was selected as the development candidate for the second program in FECD.
- Strong financial position with $330 million in cash and securities is expected to support operating runway through 2025.
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$0
Forward guidance
Design Therapeutics is focused on advancing its pipeline of GeneTAC™ small molecules, with multiple clinical trials and IND submissions planned for the near future.
Tailwinds
- Data from Phase 1 Multiple-Ascending Dose (MAD) Trial of DT-216 for Friedreich Ataxia (FA) On-track for Mid-2023.
- IND Submission On-track for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) in the Second Half of 2023.
- Myotonic Dystrophy Type-1 (DM1) Program Advancing toward IND in 2024.
- Advancing a Phase 1 MAD trial, with initial results expected in mid-2023, and final data expected by year-end. A Phase 2 trial is expected to be initiated in the second half of 2023.
- The company is working toward selection of its development candidate and anticipates submitting an IND in 2024.
Headwinds
- Risks associated with conducting a clinical trial and patient enrollment, which is affected by many factors.
- Difficulties or delays encountered with such clinical trial or patient enrollment may delay or otherwise adversely affect Design’s ongoing Phase 1 clinical trials for DT-216.
- The process of discovering and developing therapies that are safe and effective for use as human therapeutics and operating as a development stage company.
- Design’s ability to develop, initiate or complete preclinical studies and clinical trials for its product candidates.
- The risk that promising early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro